ANDA 90883, held by Lannett Co Inc. Ondansetron Hydrochloride.
As of Nov 16, 2026, ANDA 90883 (Ondansetron Hydrochloride), held by Lannett Co Inc, was first approved by FDA on Aug 5, 2010, with 9 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 5, 2010 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ondansetron HydrochlorideEQ 2MG BASE/ML · injectable;injection | Ondansetron Hydrochloride | Discontinued |
| Apr 19, 2023 | Supplement 9Labeling · Standard review | Approved | None posted |
| Apr 19, 2023 | Supplement 8Labeling · Standard review | Approved | None posted |
| Sep 2, 2016 | Supplement 7Labeling · Standard review | Approved | None posted |
| Sep 2, 2016 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jan 16, 2015 | Supplement 5Labeling · Standard review | Approved | None posted |
| Aug 8, 2013 | Supplement 4Labeling · Standard review | Approved | None posted |
| Feb 10, 2012 | Supplement 3Labeling | Approved | None posted |
| Sep 30, 2011 | Supplement 2Labeling | Approved | None posted |
| Jul 22, 2011 | Supplement 1Labeling | Approved | None posted |
| Aug 5, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters